Company intelligence / Profile preview
Concentra Biosciences
Cambridge, Massachusetts, United Statesconcentrabiosciences.com ↗
- Ownership
- Public · CON
- Development stage
- Preclinical
01
Overview
Concentra Biosciences is actively acquiring biotech companies with various clinical-stage assets. Recent acquisitions include Theseus Pharmaceuticals (February 2024), Kronos Bio (May 2025), and Allakos (April 2025).
- Therapeutic areas
- Oncology
- Modalities
- Small molecule therapeutics
- Industry
- Biotech
02
Drug pipeline
25 assets24 more assets in the full pipeline.
03
Financials
- Market cap
- $5.4B
- Total revenue
- $2.2B
- Enterprise value
- $5.9B
Beyond the preview
Go deeper on Concentra Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Concentra Biosciences.